We designed AM1241, a selective CB2 cannabinoid receptor agonist, and used it to test the hypothesis that CB2 receptor activation would reverse the sensory hypersensitivity observed in neuropathic pain states. AM1241 exhibits high affinity and selectivity for CB 2 receptors. It also exhibits high potency in vivo. AM1241 dose-dependently reversed tactile and thermal hypersensitivity produced by ligation of the L5 and L6 spinal nerves in rats. These effects were selectively antagonized by a CB 2 but not by a CB1 receptor antagonist, suggesting that they were produced by actions of AM1241 at CB 2 receptors. AM1241 was also active in blocking spinal nerve ligation-induced tactile and thermal hypersensitivity in mice lacking CB 1 receptors (CB1 ؊/؊ mice), confirming that AM1241 reverses sensory hypersensitivity independent of actions at CB 1 receptors. These findings demonstrate a mechanism leading to the inhibition of pain, one that targets receptors localized exclusively outside the CNS. Further, they suggest the potential use of CB 2 receptor-selective agonists for treatment of human neuropathic pain, a condition currently without consistently effective therapies. CB 2 receptor-selective agonist medications are predicted to be without the CNS side effects that limit the effectiveness of currently available medications. N europathic pain is defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system (1). It affects Ϸ1% of the population and results from a variety of etiologies including trauma, infection, diabetes, immune deficiencies, ischemic disorders, and toxic neuropathies (1, 2). It can be excruciating, and some patients are unable to work or to perform normal daily activities. Neuropathic pain often responds poorly to medical therapy (3, 4) . This may be due, in part, to adverse side effects of available medications that limit drug dosage (5). Medications currently used for the treatment of neuropathic pain act on neurotransmitter systems or ion channels and typically produce significant CNS side effects. For example, gabapentin, a drug commonly used to treat neuropathic pain because of its modest side effect profile compared with other therapeutic options, produces somnolence in 19% of patients and dizziness in 17% (Neurontin prescribing information, Parke-Davis). A therapy directed at targets not found in the CNS would avoid these problems. CB 2 cannabinoid receptors are one such potential target.
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CB 2 receptor mRNA is not detected in brain (6, 7) . In addition, the CB 2 receptor-selective antagonist SR144528 did not displace the nonselective cannabinoid ligand [ 3 H]CP55,940 from binding to rat brain (7) . Finally, binding of [ 3 H]CP55,940 to mouse brain was eliminated by disruption of the CB 1 receptor gene (8) but was not affected by disruption of the CB 2 receptor gene (9) . These studies suggest that CB 2 receptors are not found in the normal CNS, although they do not fully exclude the possibility that CB 2 receptors are expressed in the CNS in small, but functionally significant, amounts. CB 2 receptor-selective agonists do not produce CNS effects typically caused by nonselective cannabinoid agonists (10, 11) . CB 2 receptors are found primarily in peripheral tissues with immune functions (6, (12) (13) (14) .
We designed AM1241, a selective CB 2 receptor agonist, and used it to test the hypothesis that CB 2 receptor activation will reverse the sensory hypersensitivity observed in neuropathic pain states without producing CNS side effects. These experiments were performed in light of the previous demonstration that AM1241 inhibits acute thermal nociception (10) .
AM1241 belongs to a class of cannabergic ligands known as aminoalkylindoles. Early on, a number of these compounds were shown to bind to the CB 1 receptor and elicit the characteristic effects produced by ⌬ 9 -tetrahydrocannabinol, the key psychoactive ingredient in Cannabis sativa. Following the discovery of the CB 2 receptor (6), the second cannabinoid receptor subtype, our group has sought to develop aminoalkylindole analogs possessing high potency and selectivity for this receptor. Our efforts were rewarded with the design and synthesis of AM1241, a compound possessing high affinity and selectivity for the CB 2 receptor. Generation of CB1 ؊/؊ Mice. CB 1 -deficient mice were generated in concert with Deltagen (Redwood City, CA), using the 1.4-kb mouse CB 1 cDNA sequence as a starting point for the generation of a CB 1 targeting vector. The CB 1 targeting vector includes 5.8 kb of genomic sequence and a 7-kb IRES-LacZ-Neo-pA cassette. Homologous recombination between the targeting vector and the wild-type CB 1 allele results in deletion of 1,223 bp of the mouse CB 1 coding sequence, encompassing bp 26-1,248, and replacement of this sequence with the IRES-LacZ-Neo-pA cassette. Linear CB 1 targeting vector was electroporated into 129͞SvJ-derived R1 embryonic stem cells. Homologous recombinant clones were identified by PCR and confirmed by Southern blot analysis using 5Ј and 3Ј probes outside of the targeting vector homology arms. Targeted clones were injected into C57BL͞6 blastocysts, and chimeras were bred to 129͞SvJ (The Jackson Laboratory) mice. Germ-line transmission was confirmed by Southern blot analysis using a 3Ј outside-region probe to confirm the presence of the predicted 5-and 11-kb HindIII fragments diagnostic of the wild-type and mutant CB 1 alleles (see Fig. 3A ). All mice analyzed in this study have the genetic background 129͞SvJ and were derived from heterozygous breeding. Genotyping of CB 1 wild-type (CB 1 ϩ/ϩ ), heterozygous (CB 1 ϩ/Ϫ ), and knockout (CB 1 Ϫ/Ϫ ) mice was carried out by using a 3-primer PCR assay (see Receptor Autoradiography. Autoradiography was conducted as described by Herkenham et al. (17) with minor modifications. Mouse brain or spinal cord cryosections (15 m) were thawmounted on Superfrost Plus slides and stored at Ϫ80°C until the day of the experiment. Slides were preincubated in 50 mM Tris⅐HCl, pH 7.4, at 25°C for 30 min. Then 50 mM Tris⅐HCl (pH 7.4)͞5% BSA containing 10 nM [ 3 H]CP55,940 (specific activity, 165 Ci͞mmol; DuPont NEN) was applied at 25°C to the tissue sections and placed horizontally in a humid chamber for 2 h at room temperature; 10 M CP55,940 was used to define nonspecific binding. Slides were washed, dried, and exposed as described (17) .
Methods
Drug Administration. Cannabinoid drugs were dissolved in dimethyl sulfoxide. AM630 is a CB 2 receptor-selective antagonist with 70-to 165-fold selectivity for binding to the CB 2 receptor in vitro (18, 19) . AM251 is a 300-fold selective CB 1 receptor antagonist (20, 21) . Drugs were administered i.p. 15 min before behavioral testing.
Spinal Nerve Ligation (SNL). L5͞L6 SNL was performed as described by Kim and Chung (22) . Animals were anesthetized with halothane. An incision was made lateral to the lumbar spine. The right L5 and L6 spinal nerves were isolated and tightly ligated distal to the dorsal root ganglion. The incision was closed, and animals were allowed to recover for 10 days. Sham-operated animals were prepared in an identical fashion except that the spinal nerves were not ligated.
Measurement of Tactile Withdrawal Threshold. Tactile withdrawal threshold was determined as described by Chaplan et al. (23) . Animals were acclimated for 30 min in suspended cages with wire mesh bottoms. The hindpaw was probed with calibrated von Frey filaments (Stoelting) applied perpendicularly to the plantar surface. A positive response was indicated by a sharp withdrawal of the paw. The 50% paw withdrawal threshold was determined by the nonparametric method of Dixon (24), in which the stimulus is incrementally increased until a positive response is obtained, then decreased until a negative result is observed. The protocol was repeated until three changes in behavior were determined. The maximal cut-off values used were 15 g for rats and 3.5 g for mice. The 50% paw withdrawal threshold was determined as 10
Xfϩk␦ ͞10,000, where Xf ϭ the value of the last von Frey filament used, k ϭ Dixon value for the positive͞ negative pattern, and ␦ ϭ the logarithmic difference between stimuli.
Measurement of Thermal Withdrawal Latency. The method of Hargreaves et al. (25) was used. Animals were acclimated within Plexiglas enclosures on a clear glass plate maintained at 30°C. A radiant heat source (high-intensity projector lamp) was focused onto the plantar surface of the paw. When the paw was withdrawn, a motion detector halted the stimulus and a timer. A maximal cut-off of 40 sec for rats and 30 sec for mice was used to prevent tissue damage.
Data Analysis. Differences in responses between groups were tested by using ANOVA followed by post hoc testing with Student's t test with Bonferroni's correction. Significance was defined as P Ͻ 0.05.
Results
AM1241 is an aminoalkylindole analog substituted at the 1 position with a methylene group linked to an N-methylpiperidine ring at the 2 position (Fig. 1A) , whereas the 3-indole substituent is a 2-iodo-5-nitrobenzoyl group. The compound has favorable physicochemical properties and can be crystallized as both the free base and its water-soluble hydrochloride salt.
The affinity of AM1241 (K i ) for the CB 2 receptor in a mouse spleen preparation was 3.4 Ϯ 0.5 nM (mean Ϯ SEM), and its affinity (K i ) for the CB 1 receptor in a rat brain preparation was 280 Ϯ 41 nM (mean Ϯ SEM) (Fig. 1B) , indicating an 82-fold selectivity for the CB 2 receptor in rodent tissue. AM1241 produced a dose-dependent inhibition of SNLinduced tactile and thermal hypersensitivity in rats (Fig. 2) . The effect of AM1241 was completely blocked by the CB 2 receptorselective antagonist, AM630, but was not affected by the CB 1 receptor-selective antagonist, AM251.
To further test whether activation of the CB 2 receptor is sufficient to inhibit nerve injury-induced sensory hypersensitivity, we constructed mice deficient in the CB 1 receptor (Fig. 3A) and studied the effects of AM1241 on SNL-induced tactile and thermal hypersensitivity in CB1 Ϫ/Ϫ mice. Disruption of the CB 1 receptor gene eliminated binding of the nonselective cannabinoid ligand [ 3 H]CP55,940 in brain and spinal cord (Fig. 3B) , indicating a total absence of cannabinoid receptors (CB 1 and CB 2 ) in the CNS. WIN55,212-2, a mixed CB 1 ͞CB 2 receptor agonist, produced significant catalepsy in CB 1 ϩ/ϩ mice but did not produce catalepsy in CB 1 Ϫ/Ϫ mice, demonstrating a functional lack of CB 2 receptor activity in vivo (data not shown).
Presurgical tactile withdrawal thresholds were lower for CB 1 Ϫ/Ϫ than for CB1
ϩ/ϩ (wild-type) mice (Fig. 4) . In contrast, presurgical thermal withdrawal latencies did not differ between CB 1 Ϫ/Ϫ and CB 1 ϩ/ϩ animals (Fig. 5 ). SNL decreased tactile withdrawal threshold in both CB 1 Ϫ/Ϫ and CB 1 ϩ/ϩ mice (Fig. 4 B and D) , whereas sham operation had no effect (Fig. 4 A and C) ; i.p. injection of AM1241 reversed SNL-induced tactile hypersensitivity. The effects of AM1241 were completely blocked by AM630 but not by AM251. In spinal nerve-ligated animals, AM1241 returned tactile withdrawal thresholds in CB 1 Ϫ/Ϫ mice to preligation values of CB 1 ϩ/ϩ animals, whereas in sham-operated CB 1 Ϫ/Ϫ mice the compound increased tactile withdrawal thresholds until they equaled those observed in CB 1 ϩ/ϩ animals. Similarly, SNL decreased thermal withdrawal latency in both CB 1 Ϫ/Ϫ and CB 1 ϩ/ϩ mice ( Fig. 5 B and D) . Conversely, sham operation had no effect (Fig. 5 A and C) ; i.p. injection of AM1241 reversed SNL-induced thermal hypersensitivity. AM1241 also prolonged thermal withdrawal latency beyond presurgical baseline values in both nerve-ligated and shamoperated animals. Again, the effects of AM1241 were completely inhibited by AM630 but not by AM251.
Discussion
Ligation of the L5 and L6 spinal nerves in experimental animals is used to model human neuropathic pain resulting from injury or disease of primary afferent neurons. SNL increases sensitivity to tactile and thermal stimuli (22) , two features commonly observed in human neuropathic pain (26) .
AM1241 reversed SNL-induced tactile and thermal hypersensitivity in rats and in mice. The effects of AM1241 were inhibited by the CB 2 receptor-selective antagonist AM630 but not by the CB 1 receptor-selective antagonist AM251, indicating that they are mediated by the CB 2 receptor. Further, the reversal by AM1241 of SNL-induced tactile and thermal hypersensitivity in CB 1 Ϫ/Ϫ mice confirms that AM1241 acts through a mechanism independent of the CB 1 receptor. AM1241 inhibited both thermal hypersensitivity, which is dependent upon intact capsaicinsensitive, small, unmyelinated C-fiber afferents as well as tactile hypersensitivity, a condition that does not seem to be mediated by C-fiber afferents but may be mediated by large, myelinated A␤ fibers (27) .
In addition to reversing nerve injury-induced thermal hypersensitivity, AM1241 prolonged thermal withdrawal latencies beyond preligation baseline values. This increase is consistent with the increased thermal withdrawal latencies observed in sham-operated animals and with the previously demonstrated thermal antinociceptive effects of CB 2 receptor activation (10) .
The greater tactile sensitivity in CB 1 Ϫ/Ϫ mice compared with CB 1 ϩ/ϩ animals suggests that CB 1 receptors modulate basal tactile sensitivity through the action of endogenous cannabinoid agonists and͞or by intrinsic activity of the receptor. In contrast, the equivalent thermal sensitivity observed in CB 1 Ϫ/Ϫ and CB 1 ϩ/ϩ mice suggests either that CB 1 receptors do not partici- pate in the modulation of basal thermal sensitivity or that compensatory changes in other regulatory systems return thermal sensitivity to normal levels in CB 1 Ϫ/Ϫ animals. Our finding of equivalent thermal sensitivity in CB 1 Ϫ/Ϫ and CB 1 ϩ/ϩ in mice is consistent with the observation by Zimmer et al. (8) that withdrawal latencies in the tail flick assay do not differ between wild-type and CB 1 knockout mice. AM1241 returned thermal withdrawal latencies in CB 1 Ϫ/Ϫ mice to preligation values of CB 1 ϩ/ϩ animals, demonstrating that it is capable of reversing the tactile hypersensitivity produced by disruption of the CB 1 re- ceptor gene as well as that induced by SNL. This observation is consistent with the finding that in sham-operated CB 1 Ϫ/Ϫ mice, AM1241 increased tactile withdrawal thresholds until they equaled those observed in CB 1 ϩ/ϩ animals. The mechanism by which AM1241 acts to reverse SNLinduced somatosensory hypersensitivity is not known. The effects of this compound are unlikely to be the result of actions in the CNS because considerable evidence suggests that CB 2 receptors are not present in the CNS (6) (7) (8) (9) . A site of action outside the CNS is consistent with our previous findings where, using site-specific injections of agonist and antagonists, we showed that the antinociceptive actions of AM1241 seem to be mediated at peripheral sites (10) .
One possibility for a peripheral mechanism of action is direct inhibition of primary afferent neurons. However, CB 2 receptor mRNA was not found in dorsal root ganglia, whereas CB 1 receptor mRNA was readily detected (28) , suggesting that CB 2 receptors are not expressed in primary afferent neurons. This result does not, however, exclude the possibility that CB 2 receptors are expressed in small, but functionally significant, amounts.
A second possibility for a peripheral mechanism is an indirect action of AM1241 to decrease the sensitivity of primary afferent neurons. Indeed, CB 2 receptors are expressed primarily on mast and immune cells (6, (12) (13) (14) , and CB 2 receptor agonists, including AM1241, have been demonstrated to have antiinflammatory effects (11, 29) . It is also known that mast and immune cells release mediators that are capable of sensitizing primary afferent neurons, including histamine, serotonin, prostaglandins, interleukin 1␤, tumor necrosis factor-␣, and nerve growth factor (30) . Therefore, activation of peripheral CB 2 receptors might decrease the sensitivity of primary afferent neurons by inhibiting the release of sensitizing substances from neighboring mast and immune cells. Congruent with the above is the observation that neurogenic inflammation seems to take place after SNL at the site of SNL and in peripheral tissues surrounding the distal terminals of primary afferent neurons. Cyclooxygenase 2-immunoreactive cells, including macrophages, are increased at the injury site in spinal nerve-ligated rats (31) , and peripheral nerve injury results in polymorphonuclear leukocyte accumulation in the periphery (32, 33) . Alternatively, CB 2 receptor activation may reverse sensory hypersensitivity by inhibiting input into a nervous system sensitized at more central locations. Sensory hypersensitivity resulting from enhanced responses to normal levels of input from peripheral terminals of sensory neurons might be blocked by inhibition of this peripheral input. CB 2 receptor activation seems to be capable of inhibiting the sensory sensitivity of peripheral terminals of primary afferent neurons in the absence of peripheral inflammation or nerve injury, as demonstrated by the ability of AM1241 to inhibit acute thermal nociception by acting at peripheral CB 2 receptors (10) .
Our data demonstrate that activity of CB 1 cannabinoid receptors is not required for the inhibition of neuropathic pain by AM1241. They do not, however, fully exclude the involvement of other receptors. For example, a putative receptor has recently been described in brain that is modulated by the cannabinoid receptor agonist WIN55,212-2 but has different pharmacological properties from the CB 1 receptor and is not inhibited by the CB 1 receptor-selective antagonist AM251 (34) . To date, this receptor has not been cloned, and its interactions with cannabinoid ligands have not been characterized.
In previous work, we have shown that AM1241 does not produce catalepsy, hypothermia, inhibition of spontaneous locomotor activity, or inhibition of performance on the rotarod apparatus (10) . Earlier data with the CB 2 receptor-selective but less potent agonist HU-308 also showed that this compound does not produce catalepsy, hypothermia, or inhibition of spontaneous locomotor activity (11) .
The results presented in this communication provide evidence that CB 2 receptor-selective agonists may be effective in treating neuropathic pain without CNS side effects. Such a therapeutic profile offers significant advantages over current therapies. In addition, the value of CB 2 receptor-selective agonists, such as AM1241, in pain therapy is enhanced by their observed effectiveness against nociceptive (10), inflammatory (29) , and neuropathic pain. Although multiple pain mechanisms may be active in the same patient (as, for example, in cancer pain), there are presently no single therapies that are consistently effective against these diverse types of pain. Our data suggest the importance of the development of CB 2 receptor-selective agonists for human therapeutics.
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